Scholarlink

Objective <p>This study aims to evaluate the effect of daily tadalafil plus dutasteride treatment on lower urinary tract symptoms (LUTS) and erectile function in men with and without a prostatic median lobe due to benign prostatic hyperplasia (BPH).</p> Materials and methods <p>Between 2018 and 2022, 96 male patients aged ≥ 40 years with LUTS/BPH and erectile dysfunction (ED) were enrolled and divided into two groups based on the presence of a prostatic median lobe. Both groups received daily tadalafil (5&#xa0;mg) and dutasteride (0.5&#xa0;mg). IPSS, IIEF-EF, Qmax, prostate volume (PV), and post-void residual volume (PVR) were assessed before and after 24 weeks. PV and intravesical prostatic protrusion (length and volume) were measured using 3D transabdominal ultrasound after adequate bladder filling.</p> Results <p>A total of 96 patients were included: 42 with a median lobe (Group 1) and 54 without (Group 2). No significant differences were observed between groups in baseline IPSS, IIEF-EF, PSA, or Qmax (<i>p</i> &gt; 0.05). After 24 weeks of treatment, both groups showed significant improvements in IPSS, IIEF-EF, and Qmax. However, IPSS reduction was greater in Group 2 (<i>p</i> = 0.012), and post-treatment IIEF-EF (<i>p</i> = 0.034) and Qmax (<i>p</i> = 0.001) were also higher compared to Group 1.</p> Conclusion <p>Daily tadalafil plus dutasteride is an effective and safe treatment for men with LUTS and ED. The presence of a prostatic median lobe may reduce treatment response. Further studies are warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The effect of the combination of tadalafil and dutasteride on lower urinary tract symptoms and erectile function in patients with and without a prostatic median lobe

  • 期刊论文

  • 发表日期：

    2026年4月9日

查看全文
  • Mehmet Ali Sezgin,
  • Bahadir Ermec,
  • Caner Baran,
  • Kenan Sabuncu,
  • Mehmet Gokhan Culha

摘要

Objective

This study aims to evaluate the effect of daily tadalafil plus dutasteride treatment on lower urinary tract symptoms (LUTS) and erectile function in men with and without a prostatic median lobe due to benign prostatic hyperplasia (BPH).

Materials and methods

Between 2018 and 2022, 96 male patients aged ≥ 40 years with LUTS/BPH and erectile dysfunction (ED) were enrolled and divided into two groups based on the presence of a prostatic median lobe. Both groups received daily tadalafil (5 mg) and dutasteride (0.5 mg). IPSS, IIEF-EF, Qmax, prostate volume (PV), and post-void residual volume (PVR) were assessed before and after 24 weeks. PV and intravesical prostatic protrusion (length and volume) were measured using 3D transabdominal ultrasound after adequate bladder filling.

Results

A total of 96 patients were included: 42 with a median lobe (Group 1) and 54 without (Group 2). No significant differences were observed between groups in baseline IPSS, IIEF-EF, PSA, or Qmax (p > 0.05). After 24 weeks of treatment, both groups showed significant improvements in IPSS, IIEF-EF, and Qmax. However, IPSS reduction was greater in Group 2 (p = 0.012), and post-treatment IIEF-EF (p = 0.034) and Qmax (p = 0.001) were also higher compared to Group 1.

Conclusion

Daily tadalafil plus dutasteride is an effective and safe treatment for men with LUTS and ED. The presence of a prostatic median lobe may reduce treatment response. Further studies are warranted.